- Report
- August 2025
- 188 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 180 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 197 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- December 2024
- 332 Pages
Global
From €3665EUR$4,197USD£3,184GBP
- Report
- September 2025
- 262 Pages
Global
From €6109EUR$6,995USD£5,307GBP
- Report
- January 2025
- 363 Pages
Global
From €4191EUR$4,799USD£3,641GBP
- Report
- December 2024
- 598 Pages
Global
From €4191EUR$4,799USD£3,641GBP
- Report
- March 2025
- 1048 Pages
Global
From €4191EUR$4,799USD£3,641GBP
- Report
- November 2024
- 240 Pages
Global
From €2096EUR$2,400USD£1,821GBP
- Report
- March 2025
- 160 Pages
Global
From €4061EUR$4,650USD£3,528GBP
- Report
- March 2025
- 211 Pages
Global
From €4061EUR$4,650USD£3,528GBP
- Report
- October 2024
- 181 Pages
Global
From €4061EUR$4,650USD£3,528GBP
- Report
- November 2024
- 256 Pages
Global
From €3930EUR$4,500USD£3,414GBP
- Report
- April 2025
- 203 Pages
Global
From €4061EUR$4,650USD£3,528GBP
- Report
- May 2025
- 90 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- August 2025
- 189 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 187 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 195 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 197 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 197 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more